Richard Francis, Teva CEO (Dylan Martinez/Reuters)
A decade after its ill-fated $40.5B megadeal, Teva pivots from generics to innovation
NEW YORK — A decade ago, Teva Pharmaceutical nearly sank its century-old business when it struck a $40.5 billion deal.
In July 2015, Teva announced …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
